Treatment for critically ill COVID patients results in significant improvement in survival rate according to new study
January 11, 2022

Patient survival doubles when Seraph 100 is used earlier during ICU stay 

MARTINEZ, Calif. – Critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) within 60 hours of ICU admission experienced a survival rate double that of patients treated after being in the ICU for 60 or more hours, according to a newly released study.

“Few treatments are available for critically ill COVID patients in the ICU. We have already seen data that demonstrates survival improvement1 – and now additional peer-reviewed data was generated that demonstrates ‘earlier is better’ when it comes to Seraph 100 use in the ICU,” said Robert Ward, ExThera Medical Chairman. “In addition, patients treated earlier in their ICU with the Seraph 100 may avoid intubation and mechanical ventilation.”

The new findings, published in Nephrology Dialysis Transplantation, found:
Survivability in ICU COVID patients that started Seraph 100 treatment within 60 hours of ICU admission was 65.5% while it was 37.5% in patients that started the treatment after more than 60 hours in the ICU.2

There is still a need for therapeutic treatment options, especially in critically ill patients, as COVID variants such as Omicron continue to emerge. The Seraph 100 is the first blood purification device to be shown to reduce both bacterial and viral loads in the bloodstream and has been used on more than 800 US and EU patients with COVID-19 since April 2020.

In 2019, the Seraph 100 was granted CE mark for the reduction of bloodstream pathogens in European Union. In April 2020, the FDA granted Authorization for Emergency Use for use in patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure.

1. Chitty et al, A Multicenter Evaluation of Blood Purification with Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19: A Preliminary Report, (2021)
2. Schmidt J., et al., Interim-analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry, Nephrology Dialysis Transplantation, 2021; gfab347, https://doi.org/10.1093/ndt/gfab347

###

About ExThera Medical Corporation
ExThera Medical Corporation develops and commercializes extracorporeal blood filtration devices, including the Seraph® 100 Microbind® Affinity Blood Filter for removing a broad range of pathogens from the bloodstream of patients. Seraph can be used in hospitals, clinics, or field hospitals to address nosocomial and community-acquired infections as well as those caused by battlefield wounds and pandemics. ExThera Medical’s extracorporeal products have demonstrated life-saving capabilities in a wide range of critically ill patients suffering from sepsis and other severe infections. With a growing body of outcome and health economic evidence from independent clinical studies, success in the DARPA Dialysis-Like Therapeutics program, and from successful clinical use in the US, the EU, and the Middle East, the company is well positioned to serve healthcare professionals and patients alike. The Seraph 100® is CE marked and commercially available in the EU and has FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in the USA.

For more information visit the company’s website at www.extheramedical.com.

About Seraph 100
As a patient’s blood flows through the Seraph 100 filter, it passes over beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby subtracted from the bloodstream. Seraph adds nothing to the bloodstream. It targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis.

For more news stories on the Seraph 100 click here.

Disclaimer
All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.

L40146 Rev A